All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Early Data With DFF332, Other Key Biomarker Analyses Continue to Inform Approaches in RCC

July 3rd 2024

Sumanta Kumar Pal, MD, FASCO, highlights key renal cell carcinoma research presented at the 2024 ASCO Annual Meeting, including early data with DFF332.

TARE Gains Traction as Suitable Alternative to TACE for Locoregional HCC Therapy

July 3rd 2024

Anjana Pillai, MD, details a patient case study and key takeaways from a presentation she gave at an OncLive® State of the Science Summit™ on locoregional therapies for HCC.

ASTRO Issues Clinical Practice Guideline For Radiation Therapy in HPV-Associated OPSCC

July 3rd 2024

The American Society for Radiation Oncology has released a guideline to characterize the place of radiation therapy in HPV-associated oropharyngeal squamous cell carcinoma.

Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer

July 2nd 2024

Patients with resectable gastric cancers achieved superior OS and pCR rates with perioperative pembrolizumab plus chemotherapy vs chemotherapy alone.

First-Line Tislelizumab Plus Chemotherapy Shows OS Benefit in PD-L1+ ESCC Subgroups

July 2nd 2024

Tislelizumab plus chemotherapy improved OS in patients with unresectable esophageal squamous cell carcinoma and a CPS or TAP score of at least 1 vs 1%.

IBI343 Is Safe, Generates Preliminary Efficacy in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

July 2nd 2024

IBI343 was well tolerated and demonstrated signs of efficacy in patients with CLDN18.2-positive advanced gastric/GEJ adenocarcinoma.

Mitazalimab/mFOLFIRINOX Is Tolerable, Generates Responses in Treatment-Naive mPDAC

July 2nd 2024

Mitazalimab plus mFOLFIRINOX yielded early efficacy signals and a manageable safety profile for the frontline treatment of patients with mPDAC.

Cilta-Cel Generates OS Benefit in R/R Myeloma After 1 Prior Therapy

July 2nd 2024

Cilta-cel improved overall survival vs standard regimens in relapsed/lenalidomide-refractory multiple myeloma after 1 prior line of therapy.

FDA Receives BLA Resubmission for Cosibelimab in Advanced CSCC

July 2nd 2024

The FDA has received a biologics license application resubmission for cosibelimab in locally advanced or metastatic cutaneous squamous cell carcinoma.

OncLive Honors 15 Cancer Care Pioneers

July 2nd 2024

OncLive honors 15 oncology leaders with the 2024 Giants of Cancer Care awards for their innovations in improving patient outcomes.

Fox Chase Cancer Center Celebrates a $20 Million Legacy of Philanthropy from Marvin and Concetta Greenberg

July 2nd 2024

Fox Chase Cancer Center celebrated a gift of $10.8 million from the Estate of Concetta “Chet” Greenberg, an ardent champion of cancer research during her life.

Dual mTORC1/mTORC2 Inhibitor Sapanisertib Shows Promise in Combination Regimens for Solid Tumors

July 2nd 2024

Vivek Subbiah, MD, details the rationale for combining sapanisertib with ziv-aflibercept or metformin and next steps for mTOR inhibitors in solid tumors.

Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer

July 1st 2024

The EMA recommends durvalumab plus chemotherapy, followed by olaparib and durvalumab for pMMR endometrial cancer, and single-agent durvalumab for dMMR disease.

Durvalumab Plus Chemo Maintains OS Benefit in Advanced Biliary Tract Cancer

July 1st 2024

Durvalumab plus chemotherapy sustained an overall survival benefit vs chemotherapy alone in locally advanced or metastatic biliary tract cancer.

Pembrolizumab Plus Bevacizumab/CAPOX Yields Responses in pMMR/MSS mCRC With High TILs

July 1st 2024

Pembrolizumab plus bevacizumab and CAPOX produced responses in pMMR/MSS metastatic colorectal cancer with high immune infiltrate.

TAP Score and CPS May Be Viable for PD-L1 Expression Measurement in Advanced Gastric Cancers

July 1st 2024

Concordance between TAP score and CPS at matched thresholds indicate their viability for assessing PD-L1 expression in advanced gastric cancers.

Nivolumab/Ipilimumab/Radiation Combo Produces Responses in Locally Advanced Rectal Cancer

July 1st 2024

The EA2201 trial evaluated nivolumab, ipilimumab, and short-course radiation therapy in patients with locally advanced rectal cancer.

Neoadjuvant Botensilimab/Balstilimab Is Active in Resectable Colon Cancer, Despite MMR Status

July 1st 2024

Botensilimab and balstilimab demonstrated pathological responses across subsets of patients with resectable colon cancer.

Anti-Inflammatory Drug Celecoxib Could Reduce Risk of Colon Cancer Recurrence For a Subset of Patients

July 1st 2024

A study found stage 3 colon cancer patients with PIK3CA mutations taking celecoxib post-surgery had longer survival and disease-free intervals.

FDA Green Lights Companion Diagnostic for Niraparib Plus Abiraterone Acetate in BRCA+ mCRPC

July 1st 2024

The FDA has approved a companion diagnostic for niraparib plus abiraterone acetate in BRCA-mutated metastatic castration-resistant prostate cancer.